Holen Sie sich die Stockscreener-App
16.94
5.55%
0.89
Handel nachbörslich:
16.88
-0.06
-0.35%
Schlusskurs vom Vortag:
$16.05
Offen:
$16.05
24-Stunden-Volumen:
2.27M
Relative Volume:
0.83
Marktkapitalisierung:
$2.14B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-8.3861
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
+7.49%
1M Leistung:
-7.63%
6M Leistung:
+56.71%
1J Leistung:
+20.66%
1-Tages-Spanne:
$15.90
$16.97
1-Wochen-Bereich:
$15.35
$16.97
52-Wochen-Spanne:
$6.78
$20.34
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
16.94 | 2.03B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
223.36 | 36.47B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
65.92 | 11.47B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
44.98 | 8.22B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
93.78 | 8.16B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
38.00 | 6.76B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
10x Genomics (TXG) Stock Trades Up, Here Is Why - Finviz
10x Genomics (TXG) Maintains Buy Rating, Price Target Raised to $20 | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Given New $20.00 Price Target at Canaccord Genuity Group - MarketBeat
How 10x Genomics Inc. stock responds to policy changesWall Street Watch & Weekly High Conviction Trade Ideas - ulpravda.ru
Aug Swings: Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumQuarterly Trade Summary & AI Driven Stock Movement Reports - Улправда
Price Action: Is 10x Genomics Inc. stock safe for conservative investorsJuly 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Is 10x Genomics Inc. stock safe for conservative investorsJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Why 10x Genomics Inc. stock could outperform in 2025CEO Change & Safe Entry Point Identification - Улправда
Is 10x Genomics Inc. (1KJ) stock attractive for growth fundsJuly 2025 Movers & Free High Accuracy Swing Entry Alerts - Улправда
Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - Улправда
What technical charts say about 10x Genomics Inc. stockJuly 2025 Summary & Free Real-Time Volume Trigger Notifications - DonanımHaber
Panic Selling: How 10x Genomics Inc. stock responds to policy changesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - ulpravda.ru
Lancaster Investment Management Purchases Shares of 621,779 10x Genomics $TXG - MarketBeat
How 10x Genomics Inc. stock benefits from strong dollarWeekly Stock Summary & Comprehensive Market Scan Insights - DonanımHaber
Is 10x Genomics Inc. stock oversold or undervaluedJuly 2025 Recap & Daily Oversold Bounce Ideas - DonanımHaber
Why 10x Genomics Inc. stock could benefit from AI revolutionEntry Point & Short-Term Trading Alerts - Улправда
Is 10x Genomics Inc. stock a safe haven assetQuarterly Performance Summary & Technical Confirmation Alerts - DonanımHaber
History Review: Why 10x Genomics Inc. stock could outperform in 2025 - Улправда
Aug Rallies: Can 10x Genomics Inc. stock weather global recession2025 Winners & Losers & Low Risk High Reward Ideas - Улправда
Can 10x Genomics Inc. stock weather global recessionMarket Activity Report & Growth Focused Investment Plans - Улправда
Bear Alert: Why 10x Genomics Inc. stock could benefit from AI revolutionQuarterly Earnings Summary & Weekly Chart Analysis and Guides - Улправда
Setup Watch: Is 10x Genomics Inc. stock safe for conservative investors2025 Major Catalysts & Weekly Top Gainers Trade List - Улправда
Market Fear: How 10x Genomics Inc. stock responds to policy changesShare Buyback & Low Risk Growth Stock Ideas - Улправда
Barclays Maintains 10x Genomics (TXG) Overweight Recommendation - Nasdaq
Caxton Associates LLP Sells 259,388 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (NASDAQ:TXG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
10x Genomics $TXG Position Increased by Nikko Asset Management Americas Inc. - MarketBeat
Why The Narrative Around 10x Genomics Is Shifting After New Institutional Buying And Product Updates - Yahoo Finance
Bellevue Group AG Buys 95,754 Shares of 10x Genomics $TXG - MarketBeat
Federated Hermes Inc. Has $9.12 Million Holdings in 10x Genomics $TXG - MarketBeat
Why 10x Genomics (TXG) stock is nosediving - MSN
TXG: Citigroup Downgrades 10x Genomics to Neutral with $18 Price Target | TXG Stock News - GuruFocus
10x Genomics (TXG) Q2 2025 Earnings Transcript - The Motley Fool
10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off - ts2.tech
Why 10x Genomics (TXG) Stock Is Nosediving - Finviz
10x Genomics' (TXG) Neutral Rating Reaffirmed at Citigroup - MarketBeat
Citigroup Downgrades 10x Genomics to Neutral From Buy, Price Target is $18 - marketscreener.com
Blue Water Life Science Advisors LP Buys New Holdings in 10x Genomics $TXG - MarketBeat
10x Genomics $TXG Shares Bought by Jump Financial LLC - MarketBeat
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders - Finviz
Panagora Asset Management Inc. Buys New Position in 10x Genomics $TXG - MarketBeat
Why 10x Genomics Inc. stock appeals to analystsMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Russell Investments Group Ltd. Increases Stock Position in 10x Genomics $TXG - MarketBeat
Is 10x Genomics Inc. (1KJ) stock among top earnings playsJuly 2025 Highlights & Low Risk Entry Point Tips - Newser
Market Fear: Is CPSR stock trading at a premium valuation2025 Performance Recap & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus
TXG: Morgan Stanley Downgrades 10x Genomics, Raises Price Target - GuruFocus
Tumor Transcriptomics Research Report 2025: An $8.71 Billion Market by 2030, Driven by Rising Global Cancer Prevalence and Advancements in Genomic Sequencing Technologies - GlobeNewswire Inc.
TXG Technical Analysis & Signals — Is 10x Genomics, Inc. Stock a Buy or Sell? - Meyka
Jefferies Financial Group Inc. Decreases Position in 10x Genomics $TXG - MarketBeat
Aug Levels: Why 10x Genomics Inc. stock could benefit from AI revolutionJuly 2025 Institutional & Verified Technical Trade Signals - BỘ NỘI VỤ
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):